{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:51:08Z","timestamp":1785840668405,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03246-5","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:31:09Z","timestamp":1785839469000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Add-on safinamide and amantadine in Filipino Parkinson\u2019s disease patients with motor fluctuations: a retrospective exploratory cohort study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4650-3692","authenticated-orcid":false,"given":"Yvone Noelle A.","family":"Sermense","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-1389","authenticated-orcid":false,"given":"Raymond L.","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Tanglao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"1","key":"3246_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3233\/JPD-202224","volume":"11","author":"G Abbruzzese","year":"2021","unstructured":"Abbruzzese G, Kulisevsky J, Bergmans B, SYNAPSES Study Investigators Group et al (2021) A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: the SYNAPSES trial. J Parkinsons Dis 11(1):187\u2013198. https:\/\/doi.org\/10.3233\/JPD-202224","journal-title":"J Parkinsons Dis"},{"key":"3246_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251329099","author":"JS Baik","year":"2025","unstructured":"Baik JS, Sung YH, Wu R-M et al (2025) Optimized use of safinamide as an add-on therapy in Asian patients with Parkinson\u2019s disease: a narrative review and expert opinion. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864251329099","journal-title":"Ther Adv Neurol Disord"},{"key":"3246_CR3","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2147\/tcrm.s139545","volume":"14","author":"S Bette","year":"2018","unstructured":"Bette S, Shpiner DS, Singer C, Moore H (2018) Safinamide in the management of patients with Parkinson\u2019s disease not stabilized on levodopa: a review of the current clinical evidence. Ther Clin Risk Manag 14:1737\u20131745. https:\/\/doi.org\/10.2147\/tcrm.s139545","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"3246_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.14802\/jmd.22196","volume":"16","author":"R Bhidayasiri","year":"2023","unstructured":"Bhidayasiri R, Ishida T, Kamei T et al (2023) Safinamide as an adjunct to levodopa in Asian and Caucasian patients with Parkinson\u2019s disease and motor fluctuations: a post hoc analysis of the SETTLE study. J Mov Disord 16(2):180\u2013190. https:\/\/doi.org\/10.14802\/jmd.22196","journal-title":"J Mov Disord"},{"issue":"2","key":"3246_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/mds.25751","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P et al (2014) Randomized trial of safinamide add-on to levodopa in Parkinson\u2019s disease with motor fluctuations. Mov Disord 29(2):229\u2013237. https:\/\/doi.org\/10.1002\/mds.25751","journal-title":"Mov Disord"},{"key":"3246_CR6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10072-023-07001-6","volume":"45","author":"R Bovenzi","year":"2023","unstructured":"Bovenzi R, Liguori C, Canesi M et al (2023) Real-world use of safinamide in motor fluctuating Parkinson\u2019s disease patients in Italy. Neurol Sci 45:573\u2013583. https:\/\/doi.org\/10.1007\/s10072-023-07001-6","journal-title":"Neurol Sci"},{"key":"3246_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.645706","volume":"12","author":"RA Hauser","year":"2021","unstructured":"Hauser RA, Walsh RR, Pahwa R et al (2021) Amantadine ER (Gocovri\u00ae) significantly increases ON time without any dyskinesia: pooled analyses from pivotal trials in Parkinson\u2019s disease. Front Neurol 12:645706. https:\/\/doi.org\/10.3389\/fneur.2021.645706","journal-title":"Front Neurol"},{"issue":"34","key":"3246_CR8","doi-asserted-by":"publisher","first-page":"57316","DOI":"10.18632\/oncotarget.17622","volume":"8","author":"M Kong","year":"2017","unstructured":"Kong M, Ba M, Ren C et al (2017) An updated meta-analysis of amantadine for treating dyskinesia in Parkinson\u2019s disease. Oncotarget 8(34):57316\u201357326. https:\/\/doi.org\/10.18632\/oncotarget.17622","journal-title":"Oncotarget"},{"issue":"1","key":"3246_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","volume":"62","author":"H Murakami","year":"2022","unstructured":"Murakami H, Shiraishi T, Umehara T et al (2022) Recent advances in drug therapy for Parkinson\u2019s disease. Intern Med 62(1):33\u201342. https:\/\/doi.org\/10.2169\/internalmedicine.8940-21","journal-title":"Intern Med"},{"key":"3246_CR10","doi-asserted-by":"publisher","first-page":"123051","DOI":"10.1016\/j.jns.2024.123051","volume":"461","author":"N Nishikawa","year":"2024","unstructured":"Nishikawa N, Hatano T, Nishioka K et al (2024) Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson\u2019s disease with wearing-off: The Japanese observational J-SILVER study. J Neurol Sci 461:123051\u2013123051. https:\/\/doi.org\/10.1016\/j.jns.2024.123051","journal-title":"J Neurol Sci"},{"key":"3246_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00702-024-02851-6","volume":"132","author":"E Oh","year":"2024","unstructured":"Oh E, Cheon S-M, Cho JW et al (2024) Efficacy and safety of safinamide in Parkinson\u2019s disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study. J Neural Transm 132:431\u2013441. https:\/\/doi.org\/10.1007\/s00702-024-02851-6","journal-title":"J Neural Transm"},{"issue":"6","key":"3246_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/mds.26159","volume":"30","author":"R Pahwa","year":"2015","unstructured":"Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L et al (2015) Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED study). Mov Disord 30(6):788\u2013795. https:\/\/doi.org\/10.1002\/mds.26159","journal-title":"Mov Disord"},{"key":"3246_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2022.100169","volume":"7","author":"RL Rosales","year":"2022","unstructured":"Rosales RL, Rosales MCE, Robles DSJ et al (2022) A community-based study on the prevalence and predisposing factors of Parkinson\u2019s disease in Barangay Mangilag Sur, Quezon Province, Philippines. Clin Parkinsonism Relat Disord 7:100169. https:\/\/doi.org\/10.1016\/j.prdoa.2022.100169","journal-title":"Clin Parkinsonism Relat Disord"},{"issue":"2","key":"3246_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.14681331.2012.03840","volume":"20","author":"AHV Schapira","year":"2012","unstructured":"Schapira AHV, Stocchi F, Borgohain R et al (2012) Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson\u2019s disease. Eur J Neurol 20(2):271\u2013280. https:\/\/doi.org\/10.1111\/j.14681331.2012.03840","journal-title":"Eur J Neurol"},{"key":"3246_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.47895\/amp.v49i1.1021","volume":"49","author":"L Shu","year":"2015","unstructured":"Shu L, Jamora RD (2015) Prevalence and Risk Factors for Dyskinesia among Filipino Patients with Parkinson\u2019s Disease. Acta Med Philipp 49:48\u201351. https:\/\/doi.org\/10.47895\/amp.v49i1.1021","journal-title":"Acta Med Philipp"},{"key":"3246_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C et al (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"key":"3246_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117012","volume":"416","author":"Y Tsuboi","year":"2020","unstructured":"Tsuboi Y, Hattori N, Yamamoto A et al (2020) Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson\u2019s disease with wearing-off: results of an open-label study. J Neurol Sci 416:117012. https:\/\/doi.org\/10.1016\/j.jns.2020.117012","journal-title":"J Neurol Sci"},{"issue":"11","key":"3246_CR18","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","volume":"36","author":"Q Wei","year":"2022","unstructured":"Wei Q, Tan Y, Xu P et al (2022) The XINDI study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson\u2019s disease with motor fluctuations. CNS Drugs 36(11):1217\u20131227. https:\/\/doi.org\/10.1007\/s40263-022-00958-6","journal-title":"CNS Drugs"},{"key":"3246_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2025.100405","volume":"13","author":"K Williams","year":"2025","unstructured":"Williams K, Curtis MA, Gombinsky L, Parmar P (2025) A meta-analysis of the long-term efficacy of Amantadine for Levodopa-induced dyskinesia in Parkinson\u2019s disease. Clin Park Relat Disord 13:100405. https:\/\/doi.org\/10.1016\/j.prdoa.2025.100405","journal-title":"Clin Park Relat Disord"},{"issue":"6","key":"3246_CR20","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/mds.22875","volume":"25","author":"YJ Zhao","year":"2010","unstructured":"Zhao YJ, Wee HL, Chan Y-H et al (2010) Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times. Mov Disord 25(6):710. https:\/\/doi.org\/10.1002\/mds.22875","journal-title":"Mov Disord"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03246-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:31:10Z","timestamp":1785839470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03246-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":20,"alternative-id":["3246"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03246-5","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.L.R. is part of the Editorial Board of the Journal of Neural Transmission and has received grants from the Michael J. Fox Foundation (including Parkinson\u2019s GP2 projects), the Research Center for Health Sciences (UST). He received travel and speaking honoraria from Ipsen Pharma, Abbvie, Viatris, Eisai, Sun Pharma, Novartis, and Otsuka. No shareholdings or other financial relationships are declared. Y.N.A.S. and M.J.T. have no interests to declare.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was reviewed by the Institutional Ethics Review Board of Metropolitan Medical Center (IRB No. IRB-MMC No. 2025\u2013006) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}